Why Humanized Antibodies from Cyagen are the Future of Biotechnology

As the world delves deeper into the realm of biotechnology, it’s become abundantly clear that Humanized antibodies are leading the charge. And there’s one company at the forefront of this exciting frontier: Cyagen. Their innovative approach is poised to revolutionize medicine as we know it, and in this blog post, we’ll explore why their Humanized antibodies are truly the future of biotech.

What are Humanized antibodies?

Humanized antibody mainly refers to the antibody re-expressed from mouse monoclonal antibody by gene cloning and DNA recombination technology. Most of its amino acid sequences are replaced by human sequences, which basically retains the affinity and specificity of the parent mouse monoclonal antibody, and reduces its heterogeneity, which is beneficial to human body application.

What are the benefits of Humanized antibodies?

One of the most important benefits of Humanized antibodies is that they are less likely to cause allergic reactions. By altering the basic structure of an antibody, it is possible to reduce its potential for causing an allergic response. Some people who are sensitive to regular antibodies can benefit from humanized versions since they are less likely to experience an allergic reaction when treated with them.

Another advantage of Humanized antibodies is that they are easier to produce and store. Since they have been modified to include Ig from humans, Humanized antibodies are resistant to degradation by the body’s immune system meaning that they will remain active for a longer period of time.


Cyagen’s Humanized antibodies provide a more effective way to treat diseases, and their versatility makes them ideal for a variety of applications. Thanks to their humanization process, Cyagen’s Humanized antibodies can bind specifically to target cells and tissues, delivering high levels of therapeutic payloads without damaging healthy cells.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button